Cy­tori bags Aza­ya drugs in as­set pur­chase; Wood­ford of­fers a mea cul­pa on North­west Bio

• Cy­tori is adding a pair of on­col­o­gy drugs to its port­fo­lio with the ac­qui­si­tions of as­sets from San An­to­nio-based Aza­ya. Aza­ya has been at work on nanopar­ti­cle drugs. Their lead pro­gram is re­served for ATI-0918, “an off-patent, com­plex, gener­ic nanopar­ti­cle li­po­so­mal for­mu­la­tion of dox­oru­bicin hy­drochlo­ride, a wide­ly used chemother­a­peu­tic agent of­ten used to treat breast can­cer, ovar­i­an can­cer, mul­ti­ple myelo­ma, and Ka­posi’s sar­co­ma.” Cy­tori is pay­ing $2 mil­lion in stock and pay­ing off a cou­ple of mil­lion in debt. Aza­ya al­so stands to gain up to $166 mil­lion for a va­ri­ety of mile­stones and deal con­tin­gen­cies. Cy­tori says AI-0918 could be ready for launch in Eu­rope in 2019, if every­thing works out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER